{"id":255142,"date":"2026-09-18T10:12:37","date_gmt":"2026-09-18T04:42:37","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=255142"},"modified":"2026-09-18T10:12:37","modified_gmt":"2026-09-18T04:42:37","slug":"latin-america-pharma-stock-rises-12-percent-in-1-year","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/latin-america-pharma-stock-rises-12-percent-in-1-year\/","title":{"rendered":"This Latin America Pharma Stock Rises 12% in 1 Year: What the Headline Hides"},"content":{"rendered":"

Caplin Point: CMP Rs 2,600 (17 Sep 2026). Verified 1Y return 11.58%. 52W range Rs 1,500.30 to Rs 2,877.30. Market cap Rs 19,639 Cr. Q1 FY27 PAT Rs 179.09 Cr.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Caplin Point Laboratories is the Latin America pharma stock that returned 11.58% in the year to 17 September 2026, rising from Rs 2,330.10 to Rs 2,600. The flat headline masks a fall to Rs 1,500.30 in March 2026 and a 73% rebound to a record Rs 2,877.30. Drivers were a ten-ANDA purchase, a Foscarnet Sodium approval and Q1 FY27 EBITDA growth of 23%, while a 194-day cash conversion cycle remains the drag.<\/p>\n<\/div>\n

This Latin America pharma stock rose approximately 12% in one year, a quiet headline hiding a violent round trip. The share closed at Rs 2,330.10 on 17 September 2025 and Rs 2,600 on 17 September 2026, a verified gain of 11.58%. It fell to Rs 1,500.30 in between, then hit a record Rs 2,877.30.<\/p>\n

The company is Caplin Point Laboratories Ltd<\/a><\/strong> (NSE: CAPLIPOINT), a Chennai drugmaker selling branded generics and injectables across Central and South America, Africa and the US. Latin America gave 76% of FY26 operating revenue, the US 18% and Africa 6%, so the Caplin Point share price tracks an emerging-market distributor with a US option.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n